Table 1. Patient baseline characteristics.
| Factor | n/N (%) |
|---|---|
| Clinical parameters | |
| Age ⩾65 years | 37/139 (27) |
| Male | 86/139 (62) |
| Caucasian | 130/139 (94) |
| IgG isotype | 75/139 (54) |
| IgA isotype | 33/139 (24) |
| Other | 31/139 (22) |
| Abnormal K/L ratio | 133/139 (96) |
| Involved light chain: K | 81/133 (61) |
| Involved light chain: L | 52/133 (39) |
| Albumin <3.5 g/dl | 67/139 (48) |
| B2M ⩾3.5 mg/l | 82/137 (60) |
| B2M >5.5 mg/l | 43/137 (31) |
| ISS stage 1 | 35/137 (26) |
| ISS stage 2 | 59/137 (43) |
| ISS stage 3 | 43/137 (31) |
| Hb <10 g/dl | 43/139 (31) |
| Creatinine ⩾2 mg/dl | 9/139 (6) |
| CRP ⩾8 mg/l | 45/139 (32) |
| LDH ⩾190 U/l | 31/139 (22) |
| BMPC ⩾33% | 93/134 (69) |
| Cytogenetic abnormalities | 57/136 (42) |
| GEP parameters | |
| GEP70 high risk | 32/139 (23) |
| GEP80 high risk | 16/139 (12) |
| GEP CD-1 subgroup | 12/139 (9) |
| GEP CD-2 subgroup | 20/139 (14) |
| GEP HY subgroup | 46/139 (33) |
| GEP LB subgroup | 10/139 (7) |
| GEP MF subgroup | 7/139 (5) |
| GEP MS subgroup | 20/139 (14) |
| GEP PR subgroup | 24/139 (17) |
| GEP proliferation index ⩾10 | 16/139 (12) |
| GEP centrosome index ⩾3 | 69/139 (50) |
| GEP 1q21 amplification | 64/139 (46) |
| DNA/CIG parameters | |
| Aneuploid | 122/139 (88) |
| Dominant diploid | 53/139 (38) |
| Dominant hyperdiploid | 81/139 (58) |
| Dominant hypodiploid | 5/139 (4) |
| Number of DNA stem lines=1 | 25/139 (18) |
| Number of DNA stem lines=2 | 97/139 (70) |
| Number of DNA stem lines >2 | 17/139 (12) |
| Any CIg <2.8 | 60/139 (43) |
| Total LCR% >50% | 28/139 (20) |
Abbreviations: B2M, beta-2-microglobulin; CD-1, cyclin D1; CD-2, cyclin D2; CIg, cytoplasmic immunoglobulin index; FDC, DNA and cytoplasmic flow cytometry; GEP, gene expression profile; Hb, hemoglobin; HY, hyperdiploid; ISS, International Staging System; LB, low bone; LCR%, light chain-restricted percentage; LDH, lactate dehydrogenase; MF, MAF/MAFB; PR, proliferation.
n/N (%) denotes number with factor/number with valid data for factor.